News | April 11, 2021
NATCO receives approval for Ibrutinib tablets from ANDA
The approval is for Ibrutinib tablets 560 mg, 420 mg, 280 mg and 140 mg strengths
The approval is for Ibrutinib tablets 560 mg, 420 mg, 280 mg and 140 mg strengths
NATCO's partner BPI plans to launch 2.5 mg, 5 mg and 7.5 mg strengths of the product shortly within the next few weeks.
ranules now has a total of 38 ANDA approvals from US FDA.
Granules now has a total of 37 ANDA approvals from US FDA (36 Final approvals and 1 tentative approvals).
Subscribe To Our Newsletter & Stay Updated
